PGP and ovarian carcinoma: While taccalonolide AF has advantages over paclitaxel in Pgp-expressing ovarian cancer cells, it has potency comparable to paclitaxel in most ovarian cancer models when the cells are continuously exposed to the drug (Table 1, Table 2 and Table 3).